A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
78estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-12 | actual | When the study began enrolling |
| Primary completion | 2026-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- T-Prolymphocytic Leukemia
- Non-Hodgkins Lymphoma
Interventions
- Drug: APG-115
- Drug: APG-2575
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose of APG-115
measured 21 days
Maximum tolerated dose of APG-115+APG-2575
measured 21 days
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed